




PHARMACEUTICAL 2018

OncoMed Pharmaceuticals Inc
Rank 283 of 342





PHARMACEUTICAL 2018

OncoMed Pharmaceuticals Inc
Rank 283 of 342

The relative strengths and weaknesses of OncoMed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OncoMed Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 35% points. The greatest weakness of OncoMed Pharmaceuticals Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is -91%, being 137% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	105,205
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	93,132
Liabilities, Non-Current	0
Other Assets	1,842
Other Compr. Net Income	29
Other Expenses	1,444
Other Liabilities	65,793
Other Net Income	828
Other Revenues	38,154
Property and Equipment	3,275
Research and Development	59,839
Selling, General and Administrative Expense	16,761

Output Variable	Value in 1000 USD
Assets	110,322
Liabilities	158,925
Expenses	78,044
Revenues	38,154
Stockholders Equity	-48,603
Net Income	-39,062
Comprehensive Net Income	-39,048
Economic Capital Ratio	-91%